{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chatzilena A"],"funding":["Medical Research Council","National Institute for Health Research (NIHR)","Engineering and Physical Sciences Research Council"],"pagination":["100552"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9728025"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25"],"pubmed_abstract":["<h4>Background</h4>Whilst other studies have reported the effectiveness of mRNA vaccination against hospitalisation, including emergency department or intensive care admission, few have assessed effectiveness against other more clinically robust indices of COVID-19 severity.<h4>Methods</h4>A prospective single-centre test-negative design case-control study of adults hospitalised with COVID-19 disease or other acute respiratory disease between 1 June 2021 and 20 July 2022. We assessed VE (vaccine effectiveness) against hospitalisation, length of stay [LOS] >3 days, WHO COVID Score >5 and supplementary oxygen FiO<sub>2</sub> (fraction inspired oxygen) >28%, conducting regression analyses controlling for age, gender, index of multiple deprivation, Charlson comorbidity index, time, and communi"],"journal":["The Lancet regional health. Europe"],"pubmed_title":["Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: A prospective test negative case-control study."],"pmcid":["PMC9728025"],"funding_grant_id":["CL-2016-25-002","MC_PC_19067","ACF-2006-25-003","EP/V051555/1","MR/V038613/1"],"pubmed_authors":["Taylor Z","Wright L","Jeenes-Flanagan M","Avon CAP Research Group","Walters R","Osborne B","Adegbite D","Ruffino G","Fox K","Grimes C","Perkins F","Lazarus R","Bellavia M","Manning N","Challen R","Cloake J","Antico R","Smart L","Suppiah S","Finn A","Maskell N","Bridgeman E","Marlow R","Heath R","Grace N","Maughan K","Morrison L","Tilzey G","Scott E","Croxford P","Griffiths O","Kinney J","Valentine G","Fleming L","Nammuni Arachchge S","Ward L","Turner A","Danon L","Clout M","Helliker K","Maseko Z","Brzezinska J","Grimwood L","King J","Milutinovic K","Sequenza P","Hyams C","Mona T","Langdon A","Chang N","Vasquez M","Friedrich Z","Kellett Wright J","Riaz T","Morley A","Bayley F","Minou K","Mackay V","Garcia Gonzalez M","Oliver J","Mitchell C","Szasz-Benczur Z","Chatzilena A","Mattocks A"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: A prospective test negative case-control study.","description":"<h4>Background</h4>Whilst other studies have reported the effectiveness of mRNA vaccination against hospitalisation, including emergency department or intensive care admission, few have assessed effectiveness against other more clinically robust indices of COVID-19 severity.<h4>Methods</h4>A prospective single-centre test-negative design case-control study of adults hospitalised with COVID-19 disease or other acute respiratory disease between 1 June 2021 and 20 July 2022. We assessed VE (vaccine effectiveness) against hospitalisation, length of stay [LOS] >3 days, WHO COVID Score >5 and supplementary oxygen FiO<sub>2</sub> (fraction inspired oxygen) >28%, conducting regression analyses controlling for age, gender, index of multiple deprivation, Charlson comorbidity index, time, and communi","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-04-12T15:08:19.19Z","creation":"2025-04-05T10:33:43.443Z"},"accession":"S-EPMC9728025","cross_references":{"pubmed":["36506791"],"doi":["10.1016/j.lanepe.2022.100552"]}}